Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ETT Completes First-in-Human Cases With its Endomina Triangulation Platform

Published: Friday, October 05, 2012
Last Updated: Thursday, October 04, 2012
Bookmark and Share
Results confirm the safety and efficacy of the device and will lead to an extended clinical trial in 2013 at four key centers in Europe.

Endo Tools Therapeutics has announced the completion of several first-in-human cases where Endo Tools' new Endomina™ triangulation platform has been used.

Endomina is a universal platform that adds triangulation to any endoscope and that can be used with any endoscopic tool available for gastro-enterologists. It allows the surgeons to perform complex movements and to use multiple tools.

Dr Vincent Huberty and Dr Mostafa Ibrahim, both from Erasme hospital in Brussels, Belgium, first used Endomina to perform complex tissue resection and anterior-posterior tissue apposition in various models.

The device was then used on four patients in April, May, July and September 2012. The first two patients showed the safety of the device and highlighted the differences between all models done previously and real patients.

For the two other patients, the team, led by Prof. Jacques Deviere, chairman of the department of gastroenterology, was able to perform a full-thickness suture in the stomach, showing its potential for pouch reduction.

It allowed the surgeons to perform all the acts and validate the functionality of the device. All patients were released after a maximum of two days.

Endomina is an innovative device that adds multiple degrees of freedom and therapeutic channels to a conventional endoscope, a device that allows surgeons to look inside the body.

It gives full freedom to gastro-enterologists to perform manipulations that were until now only possible through laparoscopic access, often referred to as "keyhole surgery".

The devices open new opportunities for advances in flexible endoscopy, and for treatment of major diseases such as obesity, type II diabetes or gastro-intestinal tract tumors.

For the patient, the use of Endomina induces reduced hospitalization and improved comfort, due to lower anesthesia requirement. For hospitals and social security systems, it means a reduced overall intervention cost.

"For years, therapeutic endoscopists have been one-armed surgeons. Endomina offers the opportunity to work with two hands and therefore to do simple things like lifting tissue or making a knot, which have not been possible up to now," said Prof. Jacques Deviere, chairman of the department of gastroenterology. "I think it is a first step towards real endoluminal surgery."

The Erasme clinical trial, focused on morbid obesity treatment, will soon be expanded to four other key centers in Europe with a target of 50 patients in 2013.

To treat morbid obesity, surgeons usually perform a restrictive surgery of the stomach. There are more than 200,000 such procedures per year in the EU, representing a market of EUR two billion.

"The initial feedback about Endomina has been outstanding and many key clinicians who have been introduced to our technology are excited about its potential for new endoluminal surgery," said Alexandre Chau CEO of Endo Tools Therapeutics.

Chau continued, "We are in the process of raising funds to get to the next step of our development and put the device on the market in the EU."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Endo Tools Therapeutics Secures EUR 2.5 Million in Second Round Funding
The investment provides Endo Tools Therapeutics with funding for clinical trials in obesity treatment, to take place in 2013 and 2014.
Wednesday, September 11, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!